Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States

References

• Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39
   PubMedGoogle Scholar
• Cao H, Zhang Y. Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev 2008;32:972-83
   Google Scholar
• Gureje O, Von Korff M, Simon G, et al. Persistent pain and well-being: a World Health Organization Study in primary care. JAMA 1998;280:147-51
   PubMed Web of Science ®Google Scholar
• National Pharmaceutical Council Inc (NPC). Joint Commission on Accreditation of Healthcare Organizations. Pain: current understanding of assessment, management, and treatments. Reston, VA: National Pharmaceutical Council, 2001. Available at http://d.scribd.com/docs/1qeor4k1bd6nmb8g71hj.pdf. [Last accessed April 20, 2010]
   Google Scholar
• Chou R, Fanciullo G, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J P 2009;10:113-30
   Google Scholar
• Caldwell J, Hale M, Boyd R, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9
   PubMed Web of Science ®Google Scholar
• Roth S, Fleischmann R, Burch F, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112:810–33
   Google Scholar
• Janssen-Ortho Inc and Johnson & Johnson. Tapentadol clinical trial protocol PAI-3008. TItusville, NJ. 2009
   Google Scholar
• Janssen-Ortho Inc and Johnson & Johnson. Tapentadol clinical trial protocol PAI-3009. TItusville, NJ. 2009
   Google Scholar
• Janssen-Ortho Inc and Johnson & Johnson. Tapentadol clinical trial protocol PAI-3011. TItusville, NJ. 2009
   Google Scholar
• Frei A, Andersen S, Hole P, et al. A one year economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003;17:5-26
   PubMedGoogle Scholar
• Greiner W, Lehmann K, Earnshaw S, et al. Economic evaluation of Durogesic in moderate to severe, nonmalignant chronic pain in Germany. Eur J Health Econ 2006;7:290-6
   PubMedGoogle Scholar
• Neighbors D, Bell T, Wilson J, et al. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage 2001;21:129-43
   PubMed Web of Science ®Google Scholar
• Ward A, Bozkaya D, Fleischmann J, et al. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin 2007;23:2333-45
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
   PubMed Web of Science ®Google Scholar
• Gregorian RJ, Gasik A, Kwong W, et al. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain Palliat Care Pharmacother 2010;11:1095-108
   Google Scholar
• Labby D, Koder M, Amann T. Opioids and chronic non-malignant pain: a clinician’s handbook. Portland, OR: CareOregon, Inc. 2003. Available at http://www.careoregon.org/Providers/PharmacyHelpDesk.aspx. [Last accessed August 2010]
   Google Scholar
• Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100(1 Suppl):S5-21
   Google Scholar
• Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005;64:1727-30
   PubMed Web of Science ®Google Scholar
• Schmier J, Palmer C, Flood E, et al. Utility assessments of opioid treatment for chronic pain. Pain Med 2002;3:218-30
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS national prescription audit. IMS Health: Falls Church, VA, 2012 [Last accessed June 15, 2012]
   Google Scholar
• Ikenberg R, Hertel N, Moore RA, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ 2012;15:724-36
   PubMedGoogle Scholar
• Obradovic M, Ikenberg R, Hertel N, et al. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther 2012;34:926-43
   PubMed Web of Science ®Google Scholar
• Oderda G, Evans S, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manage 2003;25:276-83
   PubMed Web of Science ®Google Scholar
• Oderda G, Said Q, Evans R, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother 2007;41:400-7
   PubMed Web of Science ®Google Scholar
• Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009;5:137-44
   PubMedGoogle Scholar
• Hjalte F, Berggren A, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696-703
   PubMed Web of Science ®Google Scholar
• Iyer S, Davis K, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care 2010;19:44-51
   PubMedGoogle Scholar
• Anastassopoulos K, Chow W, Ackerman S, et al. Frequency and bothersomeness of side effects in pain patients taking oxycodone immediate release: impact on prescripti on and over-the-counter medication use [poster]. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting; May 16-20, 2009; Orlando, FL
   Google Scholar
• Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Chancellor J, Martin M, Liedgens H, et al. Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids. Value Health 2012;15:106-17
   PubMed Web of Science ®Google Scholar
• Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Wild J, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27
   PubMed Web of Science ®Google Scholar